From Yahoo Finance: 2025-04-26 12:50:00

Akeso and Summit Therapeutics’ ivonescimab gained approval in China as a rival to Merck’s Keytruda, but data on patient survival did not meet analyst expectations. An interim analysis showed a 22% reduced risk of death with a hazard ratio of 0.784, though not statistically significant. Summit’s shares fell 37% to $23.21. BioNTech dropped 17% to $100.06 in sympathy.



Read more at Yahoo Finance: Akeso survival data for ivonescimab misses expectations, STAT says